Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 121 to 130 of 471 total matches.

Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
prolongation and cardiac arrythmias.1,2 The macrolide antibiotics erythromycin and azithromycin ...
The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D2) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide (Reglan, and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):5-7 | Show Introduction Hide Introduction

Cladribine (Mavenclad) for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 29, 2019  (Issue 1577)
(PML) compared to other MS treatments.1-3 Oral fingolimod (Gilenya), teriflunomide (Aubagio ...
The FDA has approved cladribine (Mavenclad – EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of MS. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS.
Med Lett Drugs Ther. 2019 Jul 29;61(1577):118-20 | Show Introduction Hide Introduction

Expanded Table: Some Drugs for Smoking Cessation (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 15, 2019  (Issue 1576)
) Nicotine transdermal patch – generic NicoDerm CQ (GSK) 7, 14, 21 mg/24 hr patches 1 patch/day ...
View the Expanded Table: Some Drugs for Smoking Cessation
Med Lett Drugs Ther. 2019 Jul 15;61(1576):e112-4 | Show Introduction Hide Introduction

IV Artesunate for Severe Malaria

   
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020  (Issue 1604)
in children and adults. It has been available from the CDC on a compassionate use basis since 2007.1 ...
Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis since 2007. Artemether/lumefantrine (Coartem), another artemisinin-based drug, was approved earlier for oral treatment of uncomplicated Plasmodium falciparum malaria. IV artesunate is now the only FDA-approved injectable antimalarial drug available in the US; IV quinidine has been discontinued.
Med Lett Drugs Ther. 2020 Aug 10;62(1604):121-4 | Show Introduction Hide Introduction

An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
. Pronunciation Key Symjepi: sim jep’ ee Table 1. Epinephrine Products for Anaphylaxis Epinephrine Injection ...
The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):25-6 | Show Introduction Hide Introduction

COVID-19 Vaccine Comparison Chart (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
doses (0.3 mL) 21 days apart 2 doses (0.5 mL) 28 days apart 1 dose (0.5 mL) 2 doses 4-12 weeks ...
View the COVID-19 Vaccine Comparison Chart
Med Lett Drugs Ther. 2021 Apr 5;63(1621):e1-12 | Show Introduction Hide Introduction

Safinamide (Xadago) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
can be problematic as the disease advances and higher doses are required.1-3 Adding a dopamine ...
The FDA has approved the monoamine oxidase type B (MAO-B) inhibitor safinamide (Xadago – US Worldmeds) as an adjunct to levodopa/carbidopa for management of "off" episodes in patients with Parkinson’s disease (PD). It is the first reversible MAO-B inhibitor to be approved for this indication. Selegiline (Eldepryl, and others) and rasagiline (Azilect, and generics), two irreversible MAO-B inhibitors, have been used alone and as adjuncts to levodopa/carbidopa for many years. Safinamide is not approved for use as monotherapy.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):151-3 | Show Introduction Hide Introduction

Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea

   
The Medical Letter on Drugs and Therapeutics • Mar 11, 2019  (Issue 1567)
of TD.1) Most patients are infected via fecaloral transmission from contaminated food or water ...
The FDA has approved rifamycin (Aemcolo – Cosmo/ Aries), a minimally absorbed oral antibiotic, for treatment of adults with travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli. It is not recommended for treatment of diarrhea that is complicated by fever and/or bloody stools. Topical and injectable formulations of rifamycin have been used in Europe for other indications for many years.
Med Lett Drugs Ther. 2019 Mar 11;61(1567):39-40 | Show Introduction Hide Introduction

Talicia - A 3-Drug Combination for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020  (Issue 1599)
patient adherence to multidrug regimens.1 When available, susceptibility testing should be used to guide ...
The FDA has approved a fixed-dose combination of omeprazole, amoxicillin, and rifabutin (Talicia – RedHill) for treatment of Helicobacter pylori infection in adults. Talicia is the first rifabutin-based product to be approved for this indication.
Med Lett Drugs Ther. 2020 Jun 1;62(1599):83-5 | Show Introduction Hide Introduction

Oriahnn for Fibroid-Associated Heavy Menstrual Bleeding

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis.1 The GnRH ...
Oriahnn (Abbvie), a fixed-dose combination of the gonadotropin-releasing hormone (GnRH) receptor antagonist elagolix, the estrogen estradiol, and the progestin norethindrone acetate copackaged with elagolix alone, has been approved by the FDA for oral treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is the first product to be approved in the US for this indication. Elagolix (Orilissa) has been available since 2018 for treatment of moderate to severe pain associated with endometriosis. The GnRH receptor antagonist...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):51-2 | Show Introduction Hide Introduction